Clinical trial
NVALT 28/ PRL01 Durvalumab and Low-dose Prophylactic Cranial Irradiation (PCI) Versus Durvalumab and Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer: A Phase III Randomized Study
NCT04597671 is registered in ClinicalTrials.gov with Association NVALT Studies as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- NVALT 28/ PRL01 Durvalumab and Low-dose Prophylactic Cranial Irradiation (PCI) Versus Durvalumab and Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer: A Phase III Randomized Study
- Lead sponsor
- Association NVALT Studies
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- December 6, 2021
- Completion date
- December 31, 2032
- Enrollment
- 170 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.